Apogee Therapeutics Inc. (NASDAQ:APGE – Get Free Report) CEO Michael Thomas Henderson sold 20,000 shares of the business’s stock in a transaction dated Wednesday, May 13th. The shares were sold at an average price of $82.09, for a total transaction of $1,641,800.00. Following the completion of the transaction, the chief executive officer owned 1,115,987 shares in the company, valued at approximately $91,611,372.83. The trade was a 1.76% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Michael Thomas Henderson also recently made the following trade(s):
- On Wednesday, April 8th, Michael Thomas Henderson sold 20,000 shares of Apogee Therapeutics stock. The shares were sold at an average price of $82.58, for a total transaction of $1,651,600.00.
- On Wednesday, March 11th, Michael Thomas Henderson sold 20,000 shares of Apogee Therapeutics stock. The shares were sold at an average price of $74.78, for a total transaction of $1,495,600.00.
Apogee Therapeutics Price Performance
NASDAQ APGE opened at $81.14 on Monday. The company’s 50 day moving average is $81.24 and its 200-day moving average is $74.21. Apogee Therapeutics Inc. has a 12-month low of $34.34 and a 12-month high of $95.32. The firm has a market cap of $5.02 billion, a P/E ratio of -18.74 and a beta of 0.69.
Hedge Funds Weigh In On Apogee Therapeutics
A number of hedge funds and other institutional investors have recently bought and sold shares of APGE. Rockefeller Capital Management L.P. purchased a new position in Apogee Therapeutics in the 4th quarter worth approximately $25,000. ANTIPODES PARTNERS Ltd grew its stake in Apogee Therapeutics by 41.2% in the 3rd quarter. ANTIPODES PARTNERS Ltd now owns 843 shares of the company’s stock worth $33,000 after buying an additional 246 shares in the last quarter. Los Angeles Capital Management LLC purchased a new position in Apogee Therapeutics in the 4th quarter worth approximately $37,000. Quantbot Technologies LP purchased a new position in Apogee Therapeutics in the 3rd quarter worth approximately $96,000. Finally, Seven Fleet Capital Management LP purchased a new position in Apogee Therapeutics in the 4th quarter worth approximately $136,000. Hedge funds and other institutional investors own 79.04% of the company’s stock.
Analyst Upgrades and Downgrades
Several research firms have recently issued reports on APGE. Royal Bank Of Canada lowered their price target on shares of Apogee Therapeutics from $83.00 to $82.00 and set a “sector perform” rating on the stock in a research report on Monday, March 2nd. BTIG Research reissued a “buy” rating and issued a $137.00 price target on shares of Apogee Therapeutics in a research report on Monday, March 23rd. Wedbush boosted their price target on shares of Apogee Therapeutics from $90.00 to $95.00 and gave the company an “outperform” rating in a research report on Tuesday, March 3rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Apogee Therapeutics in a research report on Monday, April 20th. Finally, Citigroup boosted their price target on shares of Apogee Therapeutics from $95.00 to $125.00 and gave the company a “buy” rating in a research report on Tuesday, March 24th. Two analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $112.73.
Check Out Our Latest Stock Analysis on Apogee Therapeutics
About Apogee Therapeutics
Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.
The company’s lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.
Featured Articles
- Five stocks we like better than Apogee Therapeutics
- Robinhood, SoFi, and Webull Are Telling Very Different Stories
- As Broadcom Eclipses $2 Trillion, Private Credit Giants Wants In
- Target the Red-Hot Spin-Off and Merger Space With These ETFs
- Samsung Joins the $1 Trillion Club as AI Memory Demand Explodes
Receive News & Ratings for Apogee Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apogee Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
